1 – Minor symptoms or signs of Patient with GBS variant demonstrates bulbar or running neuropathy but capable of autonomic features and significant disability 2 – Able to walk 10 metres or more manual work AND without assistance but unable to 2 – Able to walk without the run [Group 2] support of a stick but incapable The progressive nature of the weakness indicates a 3 – Able to walk 10 metres across an of manual work trajectory to significant disability. open space with help 3 – Able to walk with a stick, 4 – Bedridden or chairbound appliance or support Relapse in GBS treatment-related fluctuation with 5 – Requiring assisted ventilation for 4 – Confined to bed or chair initial improvement and subsequent deterioration at least part of the day bound post IVIg treatment (neurologist review required). 6 – Dead 5 – Requiring assisted ventilation The Ig request is made by a neurologist or neurologist Qualification score is defined as > 1. Revised 6 – Dead has been consulted (including by teleconference) and values for the GBS disability score are shown has approved a second dose opposite and endorsed by the SWG (Lancet AND 1978;2:750-753). Patient has demonstrated an Initial response followed Progressive weakness is being used as a by recurrent weakness with no alternative explanation criterion to require that disease progression as demonstrated by deterioration in a recent Medical has a trajectory to significant disability. Text Research Council (MRC) Sum (12) Score compared to comments will be used to capture this the MRC Sum (12) Score post Ig treatment (Kleyweg et information. al 1991). Patients with GBS variants may be able to walk yet still have significant disability and risk of progression, not measured by GBS Kleyweg, RP, van der Meché, FGA, Schmitz, PIM 1991, Disability Score. In this instance, description ‘Interobserver agreement in the assessment of muscle of symptoms will be used. strength and functional abilities in Guillain-Barré syndrome’, Muscle Nerve, vol. 14, pp. 1103–1109. It was noted that disease progression is difficult to measure or set parameters for a Approximately 10% of patients relapse, rate, therefore a textual description would which may require a second treatment be best way to assess. with Ig. A second dose of IVIg must only be on the advice of and after assessment
1 – Minor symptoms or signs of neuropathy but capable of manual work 2 – Able to walk without the support of a stick but incapable of manual work 3 – Able to walk with a stick, appliance or support 4 – Confined to bed or chair bound 5 – Requiring assisted ventilation 6 – Dead Approximately 10% of patients relapse, which may require a second treatment with Ig. A second dose of IVIg must only be on the advice of and after assessment Patient with GBS variant demonstrates bulbar or autonomic features and significant disability AND [Group 2] The progressive nature of the weakness indicates a trajectory to significant disability. Relapse in GBS treatment-related fluctuation with initial improvement and subsequent deterioration post IVIg treatment (neurologist review required). The Ig request is made by a neurologist or neurologist has been consulted (including by teleconference) and has approved a second dose AND Patient has demonstrated an Initial response followed by recurrent weakness with no alternative explanation as demonstrated by deterioration in a recent Medical Research Council (MRC) Sum (12) Score compared to the MRC Sum (12) Score post Ig treatment (Kleyweg et al 1991). Kleyweg, RP, van der Meché, FGA, Schmitz, PIM 1991, ‘Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome’, Muscle Nerve, vol. 14, pp. 1103–1109. running 2 – Able to walk 10 metres or more without assistance but unable to run 3 – Able to walk 10 metres across an open space with help 4 – Bedridden or chairbound 5 – Requiring assisted ventilation for at least part of the day 6 – Dead Qualification score is defined as > 1. Revised values for the GBS disability score are shown opposite and endorsed by the SWG (Lancet 1978;2:750-753). Progressive weakness is being used as a criterion to require that disease progression has a trajectory to significant disability. Text comments will be used to capture this information. Patients with GBS variants may be able to walk yet still have significant disability and risk of progression, not measured by GBS Disability Score. In this instance, description of symptoms will be used. It was noted that disease progression is difficult to measure or set parameters for a rate, therefore a textual description would be best way to assess.
guillain%E2%80%93barre-syndrome-gbs-including-variants.DOCX